KabiVitrum's Antithrombin III
Executive Summary
Pasteurized human antithrombin III orphan treatment, ATnativ, introduced Feb. 5. Product is for the treatment of the estimated 3,000 U.S. patients with antithrombin III deficiency. ATnativ was approved Dec. 13. By the end of February, KabiVitrum will detail product to hematologists and hospital pharmacists by mail; telemarketing is also planned. Company will detail product in conjunction with its antithrombin III diagnostic Coatest. ATnativ's wholesale price is $295/500 I.U. bottle.